NASDAQ:GRTX

Galera Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy GRTX

*Your capital is at risk

$0.100

-0.0010 (-0.99%)

At Close: Jun 03, 2026

Galera Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.81. In total, the insiders bought 87.48B and sold 2.31B GRTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.81
● Buy	87.48B shares
● Sell	2.31B shares
94% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Apr 07, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.81. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (94% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 16, 2024 Buy	Common Stock	Soffer Rochel 10 Percent Owner	10% Owner	0 Value: $0
Apr 16, 2024 Buy	Common Stock	Soffer Rochel 10 Percent Owner	10% Owner	0 Value: $0
Feb 08, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	150 000 Value: $25.7K
Feb 08, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	150 000 Value: $25.7K
Feb 07, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	150 000 Value: $25.9K
Feb 07, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	25 000 Value: $4K
Feb 07, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	25 000 Value: $4K
Feb 07, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	150 000 Value: $25.9K
Feb 06, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	25 000 Value: $5K
Feb 06, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	25 000 Value: $5K
Feb 05, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	97 402 Value: $17.9K
Feb 05, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	97 402 Value: $17.9K
Jan 30, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	335 000 Value: $60.6K
Jan 30, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	335 000 Value: $60.6K
Jan 29, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	150 000 Value: $27.0K
Jan 29, 2024 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	150 000 Value: $27.0K
Jan 05, 2024 Buy	Common Stock	Schneid Yair 10 Percent Owner	10% Owner	0 Value: $0
Jan 05, 2024 Buy	Common Stock	Schneid Yair 10 Percent Owner	10% Owner	0 Value: $0
Dec 31, 2023 Buy	Common Stock J-Other	Altamont Pharmaceutical Holdings, Llc	10% Owner	0 Value: $0
Dec 31, 2023 Buy	Common Stock J-Other	Altamont Pharmaceutical Holdings, Llc	10% Owner	0 Value: $0
Oct 31, 2023 Buy	Common Stock	Altamont Pharmaceutical Holdings, Llc 10 Percent Owner	10% Owner	0 Value: $0
Oct 31, 2023 Buy	Common Stock	Altamont Pharmaceutical Holdings, Llc 10 Percent Owner	10% Owner	0 Value: $0
Jul 01, 2023 Buy	Stock Option (Right to Buy) A-Award	West Linda Director	Director	23 382 Value: $73.0K
Apr 17, 2014 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	318 150 Value: $60.4K
Apr 17, 2014 Buy	Common Stock P-Purchase	Schneid Yair 10 Percent Owner	10% Owner	318 150 Value: $60.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GALERA THERAPEUTICS, INC.

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer...

Read Full Profile Here